23andMe bought by Regeneron in court auction

The US biotech company Regeneron has acquired 23andMe, marking the end of its bankruptcy and offering a $256 million deal despite the company's previous valuation. In exchange for its assets, Regeneron plans to keep all former employees while ensuring customer privacy and safeguarding genetic data. The acquisition aims to preserve 23andMe’s mission to advance genome health while protecting user information.